Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
61 hedge funds and large institutions have $48.6M invested in Pardes Biosciences, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 7 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less funds holding
Funds holding: 65 → 61 (-4)
24% less capital invested
Capital invested by funds: $63.8M → $48.6M (-$15.2M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
C
Chescapmanager
Baltimore,
Maryland
|
+$1.9M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$525K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$435K |
| 4 |
Morgan Stanley
New York
|
+$254K |
| 5 |
MPM
MBB Public Markets
Chicago,
Illinois
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.24M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.44M |
| 3 |
Walleye Capital
New York
|
-$451K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$320K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$305K |
PRDS Hedge Fund Activity: Q1 2023 in Review
61 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q1 2023, worth a combined $48.6M — down 24% from $63.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PRDS and 3 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 21 added.
The largest buyer was Chescapmanager, adding an estimated $1.9M. The largest seller was Goldman Sachs, cutting an estimated $2.24M.
- 61 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q1 2023, down from 65 in Q4 2022.
- Funds reported $48.6M of Pardes Biosciences, Inc. Common Stock stock for Q1 2023, down 24% quarter-over-quarter.
- 3 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q1 2023 and 7 closed out, a net change of -4 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q1 2023 was Chescapmanager, an estimated $1.9M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q1 2023 was Goldman Sachs, an estimated $2.24M sold.
Based on aggregated 13F filings for Q1 2023.